Related Experiment Videos
Pattern electroretinogram changes after intravitreal bevacizumab injection for diabetic macular edema
1Acibadem University Medical Faculty, Istanbul, Turkey. abdullah.ozkiris@asg.com.tr
Documenta Ophthalmologica. Advances in Ophthalmology
|February 9, 2010
Summary
Intravitreal bevacizumab injections improved vision and pattern electroretinogram (PERG) responses in diabetic macular edema patients. PERG measurements may help evaluate treatment efficacy.
Area of Science:
- Ophthalmology
- Diabetology
- Medical Imaging
Background:
- Diabetic macular edema (CSME) is a leading cause of vision loss in diabetic patients.
- Intravitreal bevacizumab is a potential therapeutic agent for CSME.
- Pattern electroretinogram (PERG) assesses retinal function.
Purpose of the Study:
- To investigate the efficacy of intravitreal bevacizumab for CSME.
- To evaluate the role of PERG in assessing treatment response.
Main Methods:
- 35 diabetic patients with CSME received 2.5 mg intravitreal bevacizumab.
- Outcomes included visual acuity, fundus fluorescein angiography, and PERG (P50, N95 amplitudes).
- Measurements were taken before and after treatment at multiple time points.
Main Results:
- Mean visual acuity significantly improved post-injection (LogMAR 1.1 to 0.7).
- PERG P50 and N95 amplitudes showed significant increases compared to baseline (P < .001).
- Improvement in visual acuity correlated with enhanced PERG amplitudes.
Conclusions:
- Intravitreal bevacizumab effectively improves visual acuity in diabetic macular edema.
- PERG amplitudes significantly improve following treatment, suggesting its utility in efficacy evaluation.
- Further randomized trials are warranted to confirm PERG's role in monitoring treatment response.
